Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 19/20 | 0.41 |
| ▸ | F3 | P13726 | 19/20 | 0.41 |
| ▸ | F10 | P00742 | 14/20 | 0.41 |
| ▸ | F2 | P00734 | 13/20 | 0.41 |
| ▸ | F11 | P03951 | 10/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705214 | 0.94 | F7 (0.40) | F7F3F10F2F11 | |
| SCHEMBL18892520 | 0.92 | F7 (0.39) | F7F3F10F2F11 | |
| SCHEMBL17700809 | 0.89 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL16307102 | 0.87 | F7 (0.41) | F7F3F10F2F11 | |
| SCHEMBL16307103 | 0.85 | F7 (0.42) | F7F3F10F2F11 | |
| SCHEMBL17700582 | 0.85 | F7 (0.42) | F7F3F10F2F11 | |
| SCHEMBL16307076 | 0.84 | F7 (0.42) | F7F3F10F2F11 | |
| SCHEMBL17700684 | 0.83 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL17700732 | 0.83 | F7 (0.38) | F7F3F10F2F11 | |
| SCHEMBL17705218 | 0.81 | F7 (0.40) | F7F3F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | F7 1/4885F3 14/4885F10 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.